Newsroom | 23613 results

BALTIMORE--(BUSINESS WIRE)--Pearl Diagnostics (PearlDX), a company pioneering a new generation of non-invasive tests for lung infections, today announced the publication of clinical studies supporting U.S. Food and Drug Administration (FDA) 510(k) clearance of the MycoMEIA® Aspergillus Assay in the peer-reviewed journal Clinical Infectious Diseases. The studies evaluated the urine-based assay as an aid to diagnose invasive aspergillosis (IA), a potentially life-threatening fungal infection in p...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions. “David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expe...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also wil...

BILLERICA, Mass. & BEIJING--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a global leader in precision biomarker science, and Innovita Biological Technology Co., Ltd. (SSE: 688253.SH), a leading in vitro diagnostics company in China, today announced regulatory approvals that advance access to the Quanterix SIMOA® technology and neurology biomarker testing in the Chinese market. Initially formed in 2024, the commercialization arrangement combines Quanterix’s ultra-sensitive biomarker de...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. (« MindWalk ») (NASDAQ : HYFT), une entreprise d'IA bio-native, explique aujourd'hui pourquoi la couche ontologique en cours de construction dans l'IA d'entreprise n'atteint pas la fonction biologique, et pourquoi les sciences de la vie exigent une couche de contexte biologique qui leur soit propre. ReefIQ™, la couche de contexte biologique de MindWalk pour les sciences de la vie, fournit ce qu'une ontologie horizontale ne peut offrir : un...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced the phase IIIb CROWN study met its primary endpoint, demonstrating that at six months, long-acting Cabenuva (cabotegravir + rilpivirine [CAB + RPV LA]) achieved superior rates of viral suppression compared with standard-of-care oral antiretroviral therapy (ART) in adults and adolescents living with HIV-1 who had detectable virus when they entered the...

AUSTIN, Texas--(BUSINESS WIRE)--MindWalk Holdings Corp. ("MindWalk") (NASDAQ: HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from the first day of a de...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Drug-resistant heartworm is a growing concern for veterinarians and pet owners as resistant heartworm populations emerge. New research shows that not all heartworm preventives perform equally against these resistant isolates. Macrocyclic lactone (ML) resistance means some heartworm isolates are less sensitive to the drug class used in today’s heartworm disease preventives. As ML resistance continues to challenge heartworm prevention, veterinarians need data th...

OXFORD, England--(BUSINESS WIRE)--Sensible Biotechnologies Secures $47 Million to Advance Naturally Modified mRNA Platform and Unlock Next Generation of mRNA Medicines...

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV R...